Products

Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.

Connect With Us

All Products (882)

Quick filters: Solid Tumour Hematologic Both Name A-Z Name Z-A

Therapeutic Areas

Sort by

Molecule	Drug Class / Mechanism	Oncology Type
MEDI1873 (GITR)	Costimulatory / Bispecific Agent	Solid Tumour
Molecule MEDI1873 (GITR) Therapeutic Category Immunotherapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism Costimulatory / Bispecific Agent
MEDI3617 (Anti-Ang2)	Investigational Monoclonal / ADC Agent	Solid Tumour
Molecule MEDI3617 (Anti-Ang2) Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Milatuzumab	Investigational Monoclonal / ADC Agent	Solid Tumour
Molecule Milatuzumab Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Milciclib	Gamma-Secretase / CDK Inhibitor	Solid Tumour (Sarcoma)
Molecule Milciclib Therapeutic Category Targeted Therapy (Investigational) Oncology Type Solid Tumour (Sarcoma) Drug Class / Mechanism Gamma-Secretase / CDK Inhibitor
Mirvetuximab (Ref)	Investigational Monoclonal / ADC Agent	Solid Tumour
Molecule Mirvetuximab (Ref) Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Napabucasin	Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase)	Solid Tumour
Molecule Napabucasin Therapeutic Category Targeted Therapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase)
Navicixizumab	Investigational Monoclonal / ADC Agent	Solid Tumour
Molecule Navicixizumab Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Navoximod	Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase)	Solid Tumour
Molecule Navoximod Therapeutic Category Targeted Therapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase)
Nemtabrutinib	Reversible (Non-Covalent) BTK Inhibitor	Hematologic (Lymphoma/CLL)
Molecule Nemtabrutinib Therapeutic Category Targeted Therapy (Investigational) Oncology Type Hematologic (Lymphoma/CLL) Drug Class / Mechanism Reversible (Non-Covalent) BTK Inhibitor
Nimotuzumab (Head & Neck)	Investigational Monoclonal / ADC Agent	Solid Tumour
Molecule Nimotuzumab (Head & Neck) Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Nirogacestat	Gamma-Secretase / CDK Inhibitor	Solid Tumour (Sarcoma)
Molecule Nirogacestat Therapeutic Category Targeted Therapy (Investigational) Oncology Type Solid Tumour (Sarcoma) Drug Class / Mechanism Gamma-Secretase / CDK Inhibitor
Nogapendekin Alfa Inbakicept	Investigational Monoclonal / ADC Agent	Solid Tumour
Molecule Nogapendekin Alfa Inbakicept Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent

MEDI1873 (GITR) Immunotherapy (Investigational)
Therapeutic Category Immunotherapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism Costimulatory / Bispecific Agent
MEDI3617 (Anti-Ang2) Targeted Therapy (Investigational Antibody / ADC)
Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Milatuzumab Targeted Therapy (Investigational Antibody / ADC)
Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Milciclib Targeted Therapy (Investigational)
Therapeutic Category Targeted Therapy (Investigational) Oncology Type Solid Tumour (Sarcoma) Drug Class / Mechanism Gamma-Secretase / CDK Inhibitor
Mirvetuximab (Ref) Targeted Therapy (Investigational Antibody / ADC)
Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Napabucasin Targeted Therapy (Investigational)
Therapeutic Category Targeted Therapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase)
Navicixizumab Targeted Therapy (Investigational Antibody / ADC)
Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Navoximod Targeted Therapy (Investigational)
Therapeutic Category Targeted Therapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase)
Nemtabrutinib Targeted Therapy (Investigational)
Therapeutic Category Targeted Therapy (Investigational) Oncology Type Hematologic (Lymphoma/CLL) Drug Class / Mechanism Reversible (Non-Covalent) BTK Inhibitor
Nimotuzumab (Head & Neck) Targeted Therapy (Investigational Antibody / ADC)
Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Nirogacestat Targeted Therapy (Investigational)
Therapeutic Category Targeted Therapy (Investigational) Oncology Type Solid Tumour (Sarcoma) Drug Class / Mechanism Gamma-Secretase / CDK Inhibitor
Nogapendekin Alfa Inbakicept Targeted Therapy (Investigational Antibody / ADC)
Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent

‹ 1 … 67 68 69 70 71 … 74 ›

Product Range

Company

Global Network

Products

All Products (882)

MEDI1873 (GITR)

MEDI3617 (Anti-Ang2)

Milatuzumab

Milciclib

Mirvetuximab (Ref)

Napabucasin

Navicixizumab

Navoximod

Nemtabrutinib

Nimotuzumab (Head & Neck)

Nirogacestat

Nogapendekin Alfa Inbakicept

MEDI1873 (GITR)

MEDI3617 (Anti-Ang2)

Milatuzumab

Milciclib

Mirvetuximab (Ref)

Napabucasin

Navicixizumab

Navoximod

Nemtabrutinib

Nimotuzumab (Head & Neck)

Nirogacestat

Nogapendekin Alfa Inbakicept